| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tacrolimus | CTRPv2 | pan-cancer | AAC | 0.07 | 0.05 |
| mRNA | Bortezomib | GDSC1000 | pan-cancer | AAC | -0.095 | 0.05 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | -0.099 | 0.05 |
| mRNA | cimetidine | CTRPv2 | pan-cancer | AAC | -0.13 | 0.05 |
| mRNA | procarbazine | CTRPv2 | pan-cancer | AAC | -0.077 | 0.05 |
| mRNA | Pazopanib | GDSC1000 | pan-cancer | AAC | 0.066 | 0.05 |
| mRNA | tubastatin A | GDSC1000 | pan-cancer | AAC | -0.059 | 0.05 |
| mRNA | Vandetanib | CCLE | pan-cancer | AAC | -0.091 | 0.05 |
| mRNA | BRD-K29313308 | CTRPv2 | pan-cancer | AAC | -0.071 | 0.06 |
| mRNA | sitagliptin | CTRPv2 | pan-cancer | AAC | -0.14 | 0.06 |